Check 35,000+ stocks against 26 valuation models and 37 quality factors

LNA Santé SA (0OR2) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of LNA Santé SA €48.39, price €25.20, upside +92.0%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · GB · Home France · ISIN FR0004170017

LS Some data Sep 24, 2026

LNA Santé SA

0OR2 · LSE

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value €48.39 · Strongly undervalued (+92.0%)

!Quality 58/100

✓Healthy Growth (revenue 5y +9.7 %/yr)

!Thin margins · 2.7% net margin (TTM)

✓Low debt · generates free cash flow

✓3.8% dividend yield · Well covered

!Narrow moat 36/100

!Evidence only medium, so the estimate is less certain

26 models, one by oneBear €41.17 to bull €68.61 Growth analysisrevenue history, year by year Quality 58/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch LNA Santé SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range €16.12 – €52.37 · fair‑value band €41.17 – €68.61 · the €25.20 price screens below the €48.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LNA Santé SA engages in the management and operation of healthcare facilities and medical residences for able-bodied, semi-dependent, or dependent elderly people in France. The company operates medical care and rehabilitation units; mental health clinics; health centres; and care homes. It also provides respiratory assistance and rehabilitation, cancerology, diabetology, pain management, therapeutic education for the patient and his/her family, geriatrics, enteral and parenteral nutrition, obstetrics, antenatal and postnatal, complex dressings and specific care, post-operative care, anti-cancer chemotherapy, post-chemotherapy, radiotherapy and aplasia monitoring, psychological or social care, neurological and orthopedic rehabilitation, palliative care, intensive nursing care, intravenous treatment/infusion, blood transfusion, education for the patient and his/her loved ones, paracentesis, pleural or peritoneal drainage, and other treatment services. In addition, the company offers general, ENT carcinological, digestive and urology, dental, spinal, cosmetic, gynecological and obstetric, maxillo-facial, eye, ENT, orthopedic and trauma, plastic and cosmetic facial, stomatological, urological, vascular, and visceral and digestive surgery, as well as digestive endoscopies and hepato-gastroenterology services. LNA Santé SA was founded in 1990 and is based in Vertou, France.

Stock analysis

LNA Santé SA (0OR2) currently trades at €25.20, while our model-based Fair Value estimate is €48.39, implying the stock looks roughly 47.9% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of €123.35 per share, and 23 of the 26 models we run sit above the €25.20 price.

Bear case: the Dividend Discount group reads lowest at €8.82, and 3 of the 26 models stay below the price. Evidence for this calculation is medium.

Scenario range: €41.17 (bear) to €68.61 (bull), the price of €25.20 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

LNA Santé SA reported revenue of €913M in FY2025 versus €689M in FY2021, a compound +7.3%/yr. Reported net income was €24.1M in FY2025, compounding +0.7%/yr from FY2021.

Key figures

Market cap €280M · P/E ratio 0.1 · EPS (TTM) €2.45 · Dividend yield 3.8% · Net margin 2.6% · Return on equity 7.7% · Return on assets (EBIT) 3.8% · Operating margin 8.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 92%, 0OR2 screens cheaper than that median.

Fair Value models

Bear €41.17 Fair Value €48.39 Bull €68.61

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€1.14 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF €86.71 €141.30 €222.40 79

Growth DCF €85.75 €134.57 €203.12 78

Residual Income €26.22 €27.04 €29.46 76

All 26 models by family

DCF Models

FCF DCF €86.71 €141.30 €222.40 79

Owner Earnings €128.23 €208.37 €327.42 75

5Y Revenue Exit €74.22 €123.35 €188.24 71

5Y EBITDA Exit €129.63 €235.08 €365.90 73

5Y P/E Exit €54.65 €83.88 €115.59 71

10Y Revenue Exit €76.01 €121.20 €186.90 66

10Y EBITDA Exit €111.29 €195.08 €319.89 66

10Y P/E Exit €66.23 €95.10 €132.52 64

Earnings-Based

Graham-Dodd €16.97 €73.04 €99.82 64

Lynch FV €18.72 €26.75 €34.77 61

PEG = 1.0 €18.72 €26.75 €34.77 57

EPV €48.63 €55.53 €61.29 74

Dividend Discount

Gordon GGM €5.36 €9.65 €13.29 68

DDM Multi-Stage €5.36 €8.82 €10.31 67

Multiples

P/E Multiple €41.17 €54.89 €68.61 63

P/S Multiple €31.81 €42.42 €53.02 58

P/B Multiple €31.81 €42.42 €53.02 55

EV/EBIT €97.23 €130.31 €163.39 66

EV/EBITDA €172.21 €230.30 €288.38 67

EV/Revenue €68.81 €99.17 €129.53 53

Asset-Based

NCAV (Graham) €17.06 €22.86 €34.13 54

Growth DCF

Growth DCF €85.75 €134.57 €203.12 78

Rev-Margin DCF €74.22 €122.91 €184.40 72

Economic Profit

Residual Income €26.22 €27.04 €29.46 76

ROIC Compounder €52.71 €67.25 €85.04 72

Growth Earnings

Growth-Adj P/E €32.14 €45.92 €59.70 67

Open the full fair value analysis →

Notify me when 0OR2 reaches fair value

Put 0OR2 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 55 · Market factors (momentum, volatility) 41

Profitability 26

Margins and returns on capital today

Quality Growth 56

Are margins and returns improving?

Cashflow 64

Earnings quality: real cash, not paper profit

Fin. Strength 28

Balance sheet, leverage, solvency risk

Investment 89

Disciplined investing over empire-building

Low Volatility 78

Calm price path (market factor)

Momentum 29

Price trend over the last 3–12 months (market factor)

52W Momentum 19

Distance to the 52-week high (market factor)

Net Issuance 93

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 75/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+13.1%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.7%

Start year 2020 (pandemic). Over 10 years: +7.9% a year

Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+5.5%

Earnings growth per share plus dividend.

Earnings per share, growth per year+1.7%

Dividend (yield on the price)3.8%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.7% vs 6.9%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 8%

Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far and less than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−15.6%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+5.5%

Yearly sales growth analysts expect, extended to five years.

After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −17.4% a year for the price and +3.3% for the forecasts.

Forecast 2026 (sales)+8.5%

Forecast 2027 (sales)+5.5%

Projected 2028 (sales)+5.0%

Projected 2029 (sales)+4.6%

Projected 2030 (sales)+4.2%

Watch 0OR2, get fair value alerts →

Compare LNA Santé SA with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 241 stocks

Beats the industry median on 6/11 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 58 · Above median

Fair Value upside +49.8% · Top 25%

Profitability

Return on equity (TTM) 7.7% · Below median

Return on assets 2.9% · Below median

Net margin (TTM) 2.7% · Below median

Operating margin (TTM) 8.6% · Below median

Growth and dividend

Revenue growth 11.8% · Above median

Dividend yield (TTM) 3.8% · Above median

Balance sheet

Debt / equity 0.35× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 0.1× · Cheapest 25%

P/FCF 5.5× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc HCA	$431.63	$597.97	+39%
Fresenius SE FRE	€43.64	€34.49	−21%
Dr. Sulaiman Al Habib Medical Services Group 4013	225.00 SAR	109.45 SAR	−51%
Tenet Healthcare Corporation THC	$257.93	$274.35	+6%
IHH Healthcare Berhad, an investment holding company, 5225	8.03 MYR	4.87 MYR	−39%
Apollo Hospitals Enterprise Limited APOLLOHOSP	₹8,889	₹2,908	−67%
Encompass Health Corporation EHC	$123.47	$94.47	−23%
Fresenius Medical Care AG FMS	$22.27	$45.84	+106%
DaVita Inc DVA	$178.07	$215.81	+21%
Aier Eye Hospital Group 300015	¥7.91	¥10.86	+37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LNA Santé SA · Fair Value
€48.39 +48%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0OR2" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">LNA Santé SA · Fair Value</span><br><b style="font-size:20px">€48.39</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+48%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "LNA Santé SA Fair Value". https://www.fairvalue-calculator.com/stock/0OR2

Frequently asked questions

Is LNA Santé SA (0OR2) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of €48.39 versus a price of €25.20, about +92% upside (undervalued).

What is the fair value of 0OR2?

Our model-based fair value for LNA Santé SA is €48.39 (as of Sep 24, 2026), built from audited fundamentals. The current price: €25.20.

What is the quality score of 0OR2?

LNA Santé SA has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for LNA Santé SA (0OR2)?

Our model-based price target is the fair value of €48.39 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario €41.17, optimistic scenario €68.61. It is a calculation from audited fundamentals, not an analyst target.

What is the LNA Santé SA stock forecast for 2026?

Our models put fair value at €48.39, about +92% upside versus a price of €25.20 (undervalued). Cautious scenario €41.17, optimistic scenario €68.61. The calculation is refreshed regularly with new filings.

What is the revenue of LNA Santé SA (0OR2)?

LNA Santé SA reported trailing-twelve-month revenue of about €913M (latest available figure, as of Sep 24, 2026).

Does LNA Santé SA pay a dividend?

LNA Santé SA currently shows a dividend yield of about 3.77% relative to its recent price (as of Sep 24, 2026).

What growth is priced into LNA Santé SA (0OR2)?

For today's price to be fair in a discounted-cash-flow model, LNA Santé SA would have to grow free cash flow by -15.6 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.7 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 0OR2 use?

Our models discount LNA Santé SA at 10.3 %: a base by market capitalisation (small), damped by beta 0.51, country premium for United Kingdom. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For LNA Santé SA that is -15.6 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has LNA Santé SA (0OR2) delivered so far?

Over the past 5 years revenue at LNA Santé SA grew +9.7 % a year. The price currently implies -15.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of LNA Santé SA (0OR2) growing?

The median revenue growth in the sector is +7.0 % a year. That is the yardstick for the growth priced into LNA Santé SA (-15.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of LNA Santé SA (0OR2)?

The free-cash-flow yield on the price is 22.94 %: that much free cash flow LNA Santé SA produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of LNA Santé SA (0OR2)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LNA Santé SA it is €48.39 per share (as of Sep 24, 2026), against a price of €25.20. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is LNA Santé SA stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 0OR2 trades below its calculated fair value: price €25.20, fair value €48.39, a gap of about +92% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0OR2?

No. The price is what the market pays today (€25.20); the fair value is what the company's own numbers justify (€48.39). For LNA Santé SA the two are €23.19 per share apart. That gap is exactly why we show both numbers side by side.

How much is LNA Santé SA worth?

The market values LNA Santé SA at about €280M (market capitalisation, as of Sep 24, 2026). Per share that is €25.20; our models calculate a fair value of €48.39 per share.

What do the bullish and bearish scenarios say about 0OR2?

Our models span a range for LNA Santé SA: cautious scenario €41.17, base €48.39, optimistic €68.61 per share (as of Sep 24, 2026, price €25.20). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0OR2?

LNA Santé SA trades at a price-to-earnings ratio of 0.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €48.39 is built from several models across several years.

How solid is the balance sheet of LNA Santé SA (0OR2)?

Balance-sheet figures for LNA Santé SA (as of Sep 24, 2026): return on equity 7.7%, debt of 0.35 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.

How far is 0OR2 from its 52-week high?

LNA Santé SA trades at €25.20, about 30% below its 52-week high of €36.15 and 13% above the low of €22.21 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €48.39 is for.

Which stocks are comparable to LNA Santé SA?

From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is LNA Santé SA stock attractive at the current price?

The data as of Sep 24, 2026: price €25.20, calculated fair value €48.39 (+92%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0OR2 calculated?

We run LNA Santé SA through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €48.39, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. LNA Santé SA currently trades 48 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of LNA Santé SA (0OR2)?

The closing price on Oct 2, 2026 was €25.20. Our model-based fair value is €48.39, about +92% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with LNA Santé SA right now?

The price is below even our cautious bear case (€41.17). The market is more pessimistic than our downside scenario. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.

Where does the earnings growth of LNA Santé SA (0OR2) come from?

Earnings per share at LNA Santé SA grew +4.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.7 %, EBIT margin +0.8 %, tax rate −0.8 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of LNA Santé SA

How large is the market capitalisation of LNA Santé SA (0OR2)?

The market capitalisation of LNA Santé SA is €280M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of LNA Santé SA (0OR2)?

Earnings per share at LNA Santé SA are €2.45 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of LNA Santé SA (0OR2)?

The dividend yield of LNA Santé SA is 3.8% (payout 38.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of LNA Santé SA (0OR2)?

The net margin of LNA Santé SA is 2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of LNA Santé SA (0OR2)?

The return on equity (ROE) of LNA Santé SA is 7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of LNA Santé SA (0OR2)?

On an EBIT basis the return on assets of LNA Santé SA is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of LNA Santé SA (0OR2)?

The operating margin of LNA Santé SA is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at LNA Santé SA (0OR2)?

Revenue at LNA Santé SA is growing +11.8% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at LNA Santé SA (0OR2)?

Earnings per share at LNA Santé SA are growing +35.3% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does LNA Santé SA (0OR2) carry?

The net debt of LNA Santé SA is €812M (fiscal year 2025, ≈ 13.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch LNA Santé SA in the live analysis

One click puts LNA Santé SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.